What does a stage 4B second recurrence of high-grade serous endometrial cancer with P53, pMMR, and triple-negative biomarkers mean for treatment options like Cisplatin and Doxorubicin?
This is a really complex and challenging situation, and it's completely understandable to have a lot of questions right now. Here's some Show Full Answer
What does a stage 4B second recurrence of high-grade serous endometrial cancer with P53, pMMR, and triple-negative biomarkers mean for treatment options like Cisplatin and Doxorubicin?
This is a really complex and challenging situation, and it's completely understandable to have a lot of questions right now. Here's some helpful context.
About the Biomarkers
The combination of P53 mutation, pMMR (proficient mismatch repair), and triple-negative status places this cancer in the "high copy number" molecular category. This type tends to be more aggressive and harder to treat, which unfortunately aligns with the recurrence pattern experienced.
The pMMR status is particularly important — it means the cancer did not respond as well to pembrolizumab alone, since immunotherapy works best in dMMR tumors. About the New Chemotherapy Regimen
Moving to Cisplatin and Doxorubicin makes sense given the prior treatments. Here's why this combination may be considered:
- Carboplatin and paclitaxel were already used in the first line
- Cisplatin is a platinum-based drug that works differently enough to potentially still be effective
- Doxorubicin is an anthracycline that targets rapidly dividing cancer cells and is used in recurrent cases
Important things to discuss with the oncology team:
- Whether adding a targeted therapy like bevacizumab or lenvatinib alongside chemotherapy could be beneficial
- Whether any current clinical trials are available for P53-mutated, pMMR, triple-negative cases specifically
- Cardiac monitoring, as Doxorubicin can affect heart function over time Looking Ahead
Clinical trials are showing real promise for recurrent endometrial cancer, especially with newer targeted therapies. Given this specific biomarker profile, asking the oncologist about HER2-targeted therapies may also be worth exploring, as serous endometrial cancers sometimes overexpress HER2.
This road is incredibly tough, but treatment options continue to evolve. Staying closely connected with a gynecologic oncologist who specializes in recurrent cases is the most important step right now.
June 15
Join
Your Privacy Choices
